Combined plasmapheresis and high-dose intravenous immunoglobulin treatment in systemic sclerosis for 12 months: Follow-up of immunopathological and clinical effects

Zoltán Szekanecz*, Magdolna Aleksza, Péter Antal-Szalmás, Pál Soltész, Katalin Veres, Sándor Szántó, Zoltán Szabó, Anikó Végvári, Szilvia Szamosi, Gabriella Lakos, Sándor Sipka, Gyula Szegedi, John Varga, Gabriella Szücs

*Corresponding author for this work

Research output: Contribution to journalArticle

16 Scopus citations

Abstract

Systemic sclerosis (SSc) is an autoimmune disease which involves the skin, as well as several internal organs. Most therapies available in this disease are symptomatic. Authors present a case of diffuse SSc with progressive disease not responding to currently available treatments. Therefore a 12-month protocol of repeated plasmapheresis and high-dose intravenous immunoglobulin treatment was administered with good clinical efficacy. Apart from monitoring the clinical symptoms throughout the treatment, authors also assessed a number of humoral and cellular immunolaboratory markers in order to obtain information on the immunomodulatory effects of this combined treatment in SSc.

Original languageEnglish (US)
Pages (from-to)347-350
Number of pages4
JournalClinical Rheumatology
Volume28
Issue number3
DOIs
StatePublished - Jan 1 2009

Keywords

  • Intravenous immunoglobulin
  • Plasmapheresis
  • Systemic sclerosis

ASJC Scopus subject areas

  • Rheumatology

Fingerprint Dive into the research topics of 'Combined plasmapheresis and high-dose intravenous immunoglobulin treatment in systemic sclerosis for 12 months: Follow-up of immunopathological and clinical effects'. Together they form a unique fingerprint.

  • Cite this

    Szekanecz, Z., Aleksza, M., Antal-Szalmás, P., Soltész, P., Veres, K., Szántó, S., Szabó, Z., Végvári, A., Szamosi, S., Lakos, G., Sipka, S., Szegedi, G., Varga, J., & Szücs, G. (2009). Combined plasmapheresis and high-dose intravenous immunoglobulin treatment in systemic sclerosis for 12 months: Follow-up of immunopathological and clinical effects. Clinical Rheumatology, 28(3), 347-350. https://doi.org/10.1007/s10067-008-1062-2